View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Sartorius Stedim Biotech S.A.: 1 director

A director at Sartorius Stedim Biotech S.A. sold 750,000 shares at 211.100EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last ...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Back to Near-Term Bullish on SPX and QQQ We downgraded our near-term outlook on the S&P 500 (SPX) and Nasdaq 100 (QQQ) to neutral last week (11/19/25 Compass), after being bullish since our 4/22/25 Compass, while maintaining our intermediate-term bullish outlook (as of our 5/14/25 Compass). Crucial support levels of 6480-6520 on SPX and $580-$583 on QQQ held last week, and we are right back to being near-term bullish as long as these support levels continue to hold. Just know that SPX could see...

Thermo Fisher Scientific Inc: 2 directors

Two Directors at Thermo Fisher Scientific Inc sold after exercising options/sold 5,696 shares at between 588.265USD and 594.420USD. The significance rating of the trade was 64/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary tra...

Merck KGaA: Annual update

Our credit view of this issuer reflects its track record of conservative financial policies and solid cash flow generation, constrained by its currently weak late-stage pipeline.

Moody's Ratings says Thermo Fisher's Clario acquisition expands clinic...

Moody's Ratings commented that Thermo Fisher Scientific Inc.'s (A3 positive) announcement that it entered into a definitive agreement to acquire privately held Clario Holdings, Inc. for $8.88 billion plus certain potential future payouts will add scale and earnings diversity and bolster capabilities...

Thermo Fisher Scientific Inc.: Clario acquisition expands clinical tri...

The acquisition is earnings accretive and enhances the value of services provided to research customers, while increasing leverage by about one-half turn.

Lonza Group AG: 1 director

A director at Lonza Group AG sold 60 shares at 583.353CHF and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...

Oliver Metzger ... (+2)
  • Oliver Metzger
  • Stephan Wulf
Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch